Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 4 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

Brookdale Senior Living Inc.

Deeply undervalued

Discount 63% Return to IV: +172.1%

Market implies -19.9%/yr vs model +3.7% · below model

Black Hawk Acquisition Corp

Black Hawk Acquisition Corp

Black Hawk Acquisition Corp

Bausch & Lomb Corp

Deeply overvalued

Premium +210% Return to IV: -67.7%

Market implies +22.0%/yr vs model +8.0% · above model

BIOLIFE SOLUTIONS INC

Market implies +52.5%/yr vs model +2.0% · above model

BillionToOne, Inc.

Premium +27% Return to IV: -21.3%

Market implies +5.4%/yr vs model +50.0% · below model

BELITE BIO, INC

Biomea Fusion, Inc.

Basel Medical Group Ltd

BADGER METER INC

Model IV$175.15

Discount 28% Return to IV: +38.9%

Owner yield 3.7% 10-yr IRR 10.0% · grower

Market implies +6.7%/yr vs model +14.2% · below model

Market implies +27.1%/yr vs model +2.0% · above model

BIOMARIN PHARMACEUTICAL INC

Deeply undervalued

Discount 34% Return to IV: +52.1%

Owner yield 3.3% 10-yr IRR 8.0% · grower

Market implies +5.1%/yr vs model +13.5% · below model

BRISTOL MYERS SQUIBB CO

Deeply undervalued

Model IV$174.33

Discount 64% Return to IV: +176.5%

Owner yield 10.2% 10-yr IRR 19.0% · moderate

Market implies -7.5%/yr vs model +6.1% · below model

Bionano Genomics, Inc.

Deeply undervalued

Discount 65% Return to IV: +187.0%

Market implies -23.0%/yr vs model +12.2% · below model

Burning Rock Biotech Ltd

Benitec Biopharma Inc.

Market implies +147.0%/yr

Boundless Bio, Inc.

Bolt Biotherapeutics, Inc.

Deeply undervalued

Discount 86% Return to IV: +613.7%

Market implies -42.8%/yr vs model +50.0% · below model

Bon Natural Life Ltd

Deeply undervalued

Discount 89% Return to IV: +775.0%

Market implies -50.0%/yr vs model +2.0% · below model

Deeply undervalued

Premium +49% Return to IV: -32.7%

Market implies +6.2%/yr vs model +9.2% · below model

Market implies +30.3%/yr vs model +9.2% · above model

Barinthus Biotherapeutics plc.

Market implies +5.3%/yr vs model +15.0% · below model

BioRestorative Therapies, Inc.

Market implies +49.8%/yr vs model +50.0% · in line

BOSTON SCIENTIFIC CORP

Deeply undervalued

Model IV$105.68

Discount 59% Return to IV: +143.8%

Owner yield 4.2% 10-yr IRR 10.7% · grower

Market implies -0.6%/yr vs model +12.8% · below model

BioXcel Therapeutics, Inc.

Market implies +12.5%/yr vs model +15.0% · in line

Deeply undervalued

Discount 83% Return to IV: +489.2%

Market implies -24.2%/yr vs model +8.9% · below model

BrightSpring Health Services, Inc.

Deeply overvalued

Premium +70% Return to IV: -41.3%

Market implies +20.0%/yr vs model +16.1% · above model

BrightSpring Health Services, Inc.

Model IV$187.63

Premium +3% Return to IV: -3.3%

Market implies -2.1%/yr vs model +18.7% · below model

Deeply overvalued

Premium +84% Return to IV: -45.8%

Owner yield 4.3% 10-yr IRR 7.7% · moderate

Market implies +13.9%/yr vs model +8.0% · above model

BeyondSpring Inc.

Market implies +30.5%/yr vs model +15.0% · above model

Cabaletta Bio, Inc.

Candel Therapeutics, Inc.

Market implies +144.9%/yr vs model +2.0% · above model

Caris Life Sciences, Inc.

Deeply undervalued

Discount 35% Return to IV: +54.8%

Market implies -5.8%/yr vs model +50.0% · below model

CalciMedica, Inc.

Camp4 Therapeutics Corp

Market implies +35.3%/yr vs model +50.0% · below model

Can-Fite BioPharma Ltd.

Market implies +30.1%/yr vs model +2.0% · above model

CAPRICOR THERAPEUTICS, INC.

Market implies +43.5%/yr vs model +15.0% · above model

Deeply undervalued

Discount 16% Return to IV: +19.2%

Market implies -1.9%/yr vs model +50.0% · below model

Perspective Therapeutics, Inc.

Market implies +68.0%/yr vs model +15.0% · above model

CRESCENT BIOPHARMA, INC.

Market implies +17.0%/yr vs model +50.0% · below model

Deeply overvalued

Premium +182% Return to IV: -64.5%

Market implies +14.5%/yr vs model +40.3% · below model

C4 Therapeutics, Inc.

Market implies +67.0%/yr vs model +2.0% · above model

CRYO CELL INTERNATIONAL INC

Deeply undervalued

Discount 64% Return to IV: +177.5%

Owner yield 10.3% 10-yr IRR 18.6% · steady

Market implies -11.8%/yr vs model +5.5% · below model

Concord Medical Services Holdings Ltd

Market implies +14.4%/yr vs model +2.0% · above model

Cardio Diagnostics Holdings, Inc.

Market implies +80.5%/yr vs model +50.0% · above model

Cardio Diagnostics Holdings, Inc.

Deeply undervalued

Discount 67% Return to IV: +200.0%

Market implies -25.0%/yr vs model +50.0% · below model

Deeply overvalued

Premium +326% Return to IV: -76.5%

Market implies +17.3%/yr vs model +6.4% · above model

Cadre Holdings, Inc.

Deeply overvalued

Premium +76% Return to IV: -43.2%

Owner yield 4.0% 10-yr IRR 7.8% · moderate

Market implies +14.9%/yr vs model +9.5% · above model

CDT Equity Inc.

CDT Equity Inc.

Deeply overvalued

Premium +124% Return to IV: -55.3%

Market implies +6.3%/yr vs model +5.6% · in line

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Market implies +92.0%/yr vs model +2.0% · above model

Deeply overvalued

Premium +133% Return to IV: -57.0%

Market implies +14.4%/yr vs model +10.0% · above model

Canopy Growth Corp